The ShapeTX technology platform includes RNAskip™, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix™, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid™, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. Shape Life!
Total Funding: N/A
Funding Stage: N/A
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2018
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Shape Therapeutics
Machine Learning Scientist
Seattle, WA
Data Engineer
Seattle, WA
Research Associate/Senior Research Associate, Technology Development
Seattle, WA
Recruiter/Senior Recruiter
Seattle, WA
Senior Project Manager, Operations
Seattle, WA
